⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Myeloma-Developing Regimens Using Genomics (MyDRUG)

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Myeloma-Developing Regimens Using Genomics (MyDRUG)

Official Title: Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics Guided Multi-arm Trial of Targeted Agents Alone or in Combination With a Backbone Regimen)

Study ID: NCT03732703

Study Description

Brief Summary: The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment arms. These arms have treatments specifically directed to the mutated genes. Patients that do not have a greater than 25% mutation to the genes listed can be enrolled to a non-actionable treatment arm. The genetic sequencing of the patient's tumor is required via enrollment to the MMRF002 study: Clinical-grade Molecular Profiling of Patients with Multiple Myeloma and Related Plasma Cell Malignancies. (NCT02884102).

Detailed Description: The study will enroll 228 patients enrolled to one of eight treatment arms. The study is open to patients relapsing with relapsed refractory multiple myeloma, who have * received at least one prior but no more than 3 prior therapies * exposed to both a PI and an IMiD * had early relapse after initial treatment. Relapse is defined as the IMWG uniform response criteria (Kumar et al, 2016). Early relapse as defined by at least one of the following: 1. Relapse within 3 years post autologous stem cell transplantation (ASCT) on maintenance, or 18 months if unmaintained 2. Relapse within 18 months of initial non-ASCT based therapy

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: ALL

Healthy Volunteers: No

Locations

Mayo Clinic - Arizona, Phoenix, Arizona, United States

City of Hope, Duarte, California, United States

Emory University, Atlanta, Georgia, United States

Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Beth Israel Deaconess, Boston, Massachusetts, United States

Dana Farber Cancer Institute, Boston, Massachusetts, United States

University of Michigan Health System, Ann Arbor, Michigan, United States

Karmanos Cancer Center, Detroit, Michigan, United States

Mayo Clinic - Minnesota, Rochester, Minnesota, United States

Washington University School of Medicine Division of Medical Oncology, Saint Louis, Missouri, United States

Hackensack University Medical Center, Hackensack, New Jersey, United States

Mount Sinai School of Medicine, New York, New York, United States

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Levine Cancer Institute, Charlotte, North Carolina, United States

Ohio State University College of Medicine, Columbus, Ohio, United States

UT Southwestern Medical Center, Dallas, Texas, United States

Virginia Cancer Specialists, Fairfax, Virginia, United States

Contact Details

Name: Hearn J Cho, M.D., Ph.D.

Affiliation: Multiple Myeloma Research Consortium

Role: PRINCIPAL_INVESTIGATOR

Name: Daniel Auclair, Ph.D.

Affiliation: Multiple Myeloma Research Consortium

Role: PRINCIPAL_INVESTIGATOR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: